The present disclosure generally relates to compounds having cellular anti-proliferative activities, and more particularly relates to compounds which inhibit the activity of human SMYD2, a SET and MYND domain-containing protein lysine methyltransferase.
Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2
作者:Ramzi F. Sweis、Zhi Wang、Mikkel Algire、Cheryl H. Arrowsmith、Peter J. Brown、Gary G. Chiang、Jun Guo、Clarissa G. Jakob、Steven Kennedy、Fengling Li、David Maag、Bailin Shaw、Nirupama B. Soni、Masoud Vedadi、William N. Pappano
DOI:10.1021/acsmedchemlett.5b00124
日期:2015.6.11
A lack of useful small molecule tools has precluded thorough interrogation of the biological function of SMYD2, a lysine methyltransferase with known tumor-suppressor substrates. Systematic exploration of the structure activity relationships of a previously known benzoxazinone compound led to the synthesis of A-893, a potent and selective SMYD2 inhibitor (IC50: 2.8 nM). A cocrystal structure reveals the origin of enhanced potency, and effective suppression of p53K370 methylation is observed in a lung carcinoma (A549) cell line.